China-based WuXi Biologics (HKG: 2269) is to take over the operations of one of Bayer's (BAYN: DE) final drug product manufacturing plants.
The Shanghai firm will operate the facility in Leverkusen, Germany, based on a manufacturing agreement that will be negotiated.
"WuXi Biologics will continue to expand our worldwide capacity"This facility will be a back-up site for the final product manufacturing of the hemophilia treatment, Kovaltry (octocog alfa; antihemophilic Factor [recombinant]).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze